

**RECEIVED
CENTRAL FAX CENTER**

Clark & Elbing LLP

SEP 17 2007

101 Federal Street
Boston, MA 02110

Telephone 617-428-0200
Facsimile 617-428-7045
617-428-7046

Date: September 17, 2007

To: U.S. Patent and Trademark Office
Group Art Unit 1649

Facsimile No.: 571-273-8300

From: Kristina Bicker-Brady, Ph.D.
Reg. No. 39,109

Re: U.S. Patent Application Serial No. 10/541,304
METHOD FOR TRANSPORTING A COMPOUND ACROSS
THE BLOOD-BRAIN BARRIER
Belivcau, et al.
Filed July 1, 2005
Attorney Docket No. 50546/002002
Customer No. 21559
Confirmation No. 8132

Pages: 4, including cover page.


Message: The following papers are enclosed:
Revocation and New Power of Attorney (3 pages)

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

**RECEIVED
CENTRAL FAX CENTER**

SEP 17 2007

**PATENT
ATTORNEY DOCKET NO. 50546/002002**

Certificate of Facsimile Transmission: Date of Transmission: <u>September 17, 2007</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 571-273-8300.	
Flora Katsikis Printed Name of Person Faxing Transmission	 Signature of Person Faxing Transmission

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Beliveau et al.	Confirmation No.:	8132
Serial No.:	10/541,304	Art Unit:	1615
Filed:	July 1, 2005	Examiner:	Not yet assigned
		Customer No.:	21559
Title:	METHOD FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Angiochem, Inc., a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of:

A chain of title from the inventors of the application, to the current assignee as shown below.

1. From the inventors to Universite du Quebec a Montreal as recorded in the Patent and Trademark Office at Reel 017264, Frame 0266 on November 25, 2005.

2. From Universite du Quebec a Montreal to Transfert Plus, S.E.C., as recorded in the Patent and Trademark Office at Reel 017264, Frame 0255 on November 25, 2005.

3. From Transfert Plus, S.E.C. to Angiochem, Inc., as recorded in the Patent and Trademark Office at Reel 017264, Frame 0259 on November 25, 2005.

The undersigned has reviewed all the documents in the chain of title of the application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing LLP, associated with customer number **21559**, with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should be sent to the address associated with customer number **21559**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18

of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: Sept 17 2007


Jean-Paul Castaigne, M.D.
President & CEO
Angiochem, Inc.
201 President-Kennedy Avenue
Suite PK-R210
Montreal, QC H2X 3Y7
CANADA